TP53 and cervical cancer: This study suggested that withaferin A-treated cervical cancer cells induced p53 accumulation, decreased the expression of HPV E6 and E7 oncoprotein, increased p21 level, and modulated the expression of proliferating cell nuclear antigen (PCNA) that triggered cell cycle arrest.